NCT03698019
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 448 versions: 19 with changes below, 31 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Study completion pushed from Oct 30, 2026 to Oct 30, 2027
- Minor Study completion date: Oct 30, 2026 to Oct 30, 2027
- Minor Study sites revised (815)
- Minor Study sites revised (815)
- Minor Study sites: 816 to 815v444
Show 15 earlier versionsHide 15 earlier versions
- Minor Study sites revised (816)v443
- Minor Study sites revised (816)v442
- Minor Study sites revised (816)v441
- Minor Study sites revised (816)v440
- Minor Study sites: 817 to 816v439
- Minor Study sites revised (817)v438
- Minor Study sites: 818 to 817v435
- Minor Study sites revised (818)v407
- Minor Study sites revised (818)v406
- Minor Study sites: 820 to 818
- Study completion date: Oct 31, 2025 to Oct 30, 2026
- Minor Study sites revised (820)v404
- Minor Study sites revised (820)v402
- Minor Study sites revised (820)v401
- Minor Study sites revised (820)v400
- Minor Study sites revised (820)v399
- Minor: routine updates
Endpoints
Primary
Secondary (4)
Arms and interventions
Within 17 days (preferably within 14 days) days after IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood throughout the study and MRI or CT on study.
Patients receive pembrolizumab IV over 30 minutes on day 1 every 3 weeks for 3 cycles, then undergo surgery within 3 weeks. Within 84 days, patients receive pembrolizumab IV over 30 minutes every 3 weeks for 15 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood throughout the study and MRI or CT on study.
Procedures: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Therapeutic Conventional Surgery
Biologicals: Pembrolizumab
Sites
815 sites in 1 country